NEW YORK (AP) — Horizon Pharma is buying Hyperion Therapeutics for about $1.1 billion, gaining two treatments for genetic disorders.
Search Results - stltoday.com, St. Louis Post-Dispatch: Business
Mon, 03/30/2015 - 3:42am